V.23-11978 (E)

*2311978*

International Narcotics Control Board FORM B/P

Updated: 2023

ASSESSMENT OF ANNUAL MEDICAL AND SCIENTIFIC REQUIREMENTS FOR SUBSTANCES IN SCHEDULES II, III AND IV

OF THE CONVENTION ON PSYCHOTROPIC SUBSTANCES OF 1971

(to be furnished to the International Narcotics Control Board (INCB) pursuant to Economic and Social Council resolutions 1981/7, 1991/44, 1993/38 and 1996/30)

Country or Territory: ESTONIA Date: 14.08.2024

Competent office: State Agency of Medicines

Title or function: Specialist / Bureau of Import and Export Supervision

Responsible officer’s name: Terje Parts Email: [email protected]

Telephone number(s): +372 7 374 140 Fax number(s):

Signature:

These assessments should be effective as of: September 2024

CHANGES IN ESTABLISHING ASSESSMENTS OF delta-9-TETRAHYDROCANNABINOL (delta-9-THC)

Assessments of annual medical and scientific requirements should include

quantities of delta-9-tetrahydrocannabinol (delta-9-THC) of natural and synthetic origin

This form can also be downloaded from the INCB website at:

www.incb.org, under “Psychotropic Substances/Toolkit/Form B/P and Supplement”

Please consider submitting this form using XML format.

This form should be completed and sent to:

International Narcotics Control Board

Vienna International Centre

P.O. Box 500, 1400 Vienna, Austria

Telephone: + (43) (1) 26060-4277 Facsimile: + (43) (1) 26060-5867 or 26060-5868

Email: [email protected], [email protected] Home page: www.incb.org

Form B/P

Page 2

Total quantities required annually for medical and scientific purposes

Form B/P may be used to submit assessments for all psychotropic substances to be used in the

country. Assessments should reflect the total domestic medical and scientific requirements for

one year. They should therefore include quantities to be manufactured domestically and not be

restricted to imports. Quantities needed for industrial purposes (i.e. to manufacture other substances)

should be included and the purposes should be indicated (i.e. qualitative and quantitative information

on final products). The assessments should further include requirements to be held in stock to meet

exceptional circumstances. Quantities required for exports or re-exports should not be included in the

assessments. Assessments of delta-9-THC should include quantities of natural and synthetic origin.

All Governments are encouraged to provide information on the method used to determine the

assessments furnished in Form B/P. In this context, the Guide on Estimating Requirements for

Substances under International Control, available at www.incb.org, might be useful. The Guide is

intended to assist competent national authorities in identifying methods for calculating the quantities

of controlled substances required for medical and scientific purposes and may assist authorities in

preparing the assessments of annual requirements for psychotropic substances.

Unlike estimates for narcotic drugs, the assessments for psychotropic substances are not required

to be confirmed by the International Narcotics Control Board (INCB).

INCB recommends that a revised Form B/P be submitted at least once every three years. INCB

will use reported assessments for reference during a three-year period unless a supplement to

previously submitted assessments is received. The quantities indicated on Form B/P will be used as a

guide by the authorities responsible for authorizing exports in exporting countries.

Assessments are updated on a weekly basis and placed on the INCB website at: www.incb.org,

under “Psychotropic Substances/Status of Assessments”.

Form B/P

Page 3

STATEMENT OF THE METHOD

Please provide here comments on the methods used in determining

the various assessments reported on this form and/or any changes.

One licenced company deals with the import mostly from USA of pure reference substances and solutions

(in methanol, ethanol and acetonitrile) (Reference Material (RM) and Certified Reference Material (CRM))

for the purpose of re-export to EU and Middle-East to research and forensic laboratories for scietific and

forensic purposes.

The use of Dexamfetamine, Lisdexamfetamine dimesylate and methylphenidate in the treatment of ADHD

has increased. Lisdexamfetamine dimesylate has been converted to Dexamfetamine.

delta-9-THC* - Bedrocan 5 cannabis products (flos and granular form) applied by doctors for specific

patients

Remarks

Form B/P

Page 4

Assessments of requirements for substances in Schedule II

Code Substance Kilograms Grams

PA 003 Amfetamine 120

PA 007 Amineptine 20

PA 008 AM-2201 20

PA 009 5F-APINACA (5F-AKB-48) 20

PA 010 5F-AMB-PINACA (5F-AMB, 5F-MMB-PINACA) 20

PA 011 ADB-BUTINACA 20

PB 008 2C-B 20

PC 011 AB-CHMINACA 20

PC 012 CUMYL-4CN-BINACA 20

PC 013 ADB-CHMINACA 20

PC 014 4-CMC (4-chloromethcathinone; clephedrone) 20

PC 015 CUMYL-PEGACLONE 20

PD 002 Dexamfetamine 2 920

PD 010 delta-9-THC* 2 500

PD 012 Diphenidine 20

PE 007 Ethylone 20

PE 008 Ethylphenidate 20

PE 010 Eutylone 20

PF 005 Fenetylline 20

PF 007 4-fluoroamphetamine (4-FA) 20

PF 008 FUB-AMB 20

PF 009 ADB-FUBINACA 20

PF 010 AB-FUBINACA 20

PG 002 GHB 3 000

PJ 001 JWH-018 20

PL 006 Levamfetamine 20

PL 007 Levomethamphetamine 20

PM 002 Mecloqualone 20

PM 005 Metamfetamine 20

PM 006 Methaqualone 20

PM 007 Methylphenidate 60 000

Form B/P

Page 5

PM 015 Metamfetamine racemate 20

PM 021 MDPV (3,4-methylenedioxypyrovalerone) 20

PM 022 Mephedrone (4-methylmethcathinone) 20

PM 023 Methylone (beta-keto-MDMA) 20

PM 024 Methoxetamine (MXE) 20

PM 025 MDMB-CHMICA 20

PM 026 Methiopropamine (MPA) 20

PM 027 4-methylethcathinone (4-MEC) 20

PM 028 5F-MDMB-PICA (5F-MDMB-2201) 20

PM 029 4-F-MDMB-BINACA 20

PM 030 MDMB-4en-PINACA 20

PM 031 3-Methoxyphencyclidine 20

PM 032 3-Methylmethcathinone 20

PN 009 N-benzylpiperazine (BZP) 20

PN 010 N-ethylnorpentylone (ephylone) 20

PN 011 N-ethylhexedrone 20

PP 005 Phencyclidine 20

PP 006 Phenmetrazine 20

PP 011 5F-ADB/5F-MDMB-PINACA 20

PP 018 AB-PINACA 20

PP 022 α-PVP 20

PP 023 4,4’-DMAR 20

PP 025 Pentedrone 20

PP 026 5F-PB-22 20

PP 027 alpha-PHP 20

PP 028 alpha-PiHP 20

PS 001 Secobarbital 20

PU 001 UR-144 20

PX 001 XLR-11 20

PZ 001 Zipeprol 20

Form B/P

Page 6

Assessments of requirements for substances in Schedule III

Code Substance Kilograms Grams

PA 002 Amobarbital 20

PB 004 Butalbital 20

PB 006 Buprenorphine 520

PC 001 Cyclobarbital 20

PC 009 Cathine 20

PF 002 Flunitrazepam 20

PG 001 Glutethimide 20

PP 002 Pentobarbital 176 000

PP 014 Pentazocine 20

Form B/P

Page 7

Assessments of requirements for substances in Schedule IV

Code Substance Kilograms Grams

PA 001 Amfepramone 20

PA 004 Alprazolam 5 000

PA 005 Allobarbital 20

PA 006 Aminorex 20

PB 001 Barbital 20

PB 002 Benzfetamine 20

PB 003 Bromazepam 8 500

PB 005 Butobarbital 20

PB 007 Brotizolam 20

PC 002 Camazepam 20

PC 003 Chlordiazepoxide 70

PC 004 Clobazam 1 200

PC 005 Clonazepam 3 600

PC 006 Clorazepate 20

PC 007 Clotiazepam 20

PC 008 Cloxazolam 20

PC 016 Clonazolam 20

PD 005 Delorazepam 20

PD 006 Diazepam 153 000

PD 013 Diclazepam 20

PE 001 Ethchlorvynol 20

PE 002 Ethinamate 20

PE 003 Estazolam 20

PE 004 Ethyl loflazepate 20

PE 005 Etilamfetamine 20

PE 009 Etizolam 20

PF 001 Fludiazepam 20

PF 003 Flurazepam 20

PF 004 Fencamfamin 20

PF 006 Fenproporex 20

PF 011 Flualprazolam 20

Form B/P

Page 8

PF 012 Flubromazolam 20

PH 001 Halazepam 20

PH 002 Haloxazolam 20

PK 001 Ketazolam 20

PL 001 Lefetamine, SPA 20

PL 003 Loprazolam 20

PL 004 Lorazepam 1 900

PL 005 Lormetazepam 20

PM 001 Mazindol 20

PM 003 Meprobamate 20

PM 008 Methylphenobarbital 20

PM 009 Methyprylon 20

PM 010 Medazepam 15 000

PM 012 Mefenorex 20

PM 016 Midazolam 3 500

PM 018 Mesocarb 20

PN 001 Nimetazepam 20

PN 002 Nitrazepam 2 000

PN 003 Nordazepam 20

PO 001 Oxazepam 900

PO 002 Oxazolam 20

PP 004 Phendimetrazine 20

PP 008 Phenobarbital 47 000

PP 009 Phentermine 20

PP 010 Pipradrol 20

PP 015 Pinazepam 20

PP 016 Prazepam 20

PP 019 Pyrovalerone 20

PP 020 Pemoline 20

PP 024 Phenazepam 50

PS 003 Secbutabarbital 20

PT 003 Temazepam 20

PT 004 Tetrazepam 20

Form B/P

Page 9

PT 005 Triazolam 25

PV 001 Vinylbital 20

PZ 002 Zolpidem 25 900

V.23-11978 (E)

*2311978*

International Narcotics Control Board FORM B/P

Updated: 2023

ASSESSMENT OF ANNUAL MEDICAL AND SCIENTIFIC REQUIREMENTS FOR SUBSTANCES IN SCHEDULES II, III AND IV

OF THE CONVENTION ON PSYCHOTROPIC SUBSTANCES OF 1971

(to be furnished to the International Narcotics Control Board (INCB) pursuant to Economic and Social Council resolutions 1981/7, 1991/44, 1993/38 and 1996/30)

Country or Territory: ESTONIA Date: 14.08.2024

Competent office: State Agency of Medicines

Title or function: Specialist / Bureau of Import and Export Supervision

Responsible officer’s name: Terje Parts Email: [email protected]

Telephone number(s): +372 7 374 140 Fax number(s):

Signature:

These assessments should be effective as of: September 2024

CHANGES IN ESTABLISHING ASSESSMENTS OF delta-9-TETRAHYDROCANNABINOL (delta-9-THC)

Assessments of annual medical and scientific requirements should include

quantities of delta-9-tetrahydrocannabinol (delta-9-THC) of natural and synthetic origin

This form can also be downloaded from the INCB website at:

www.incb.org, under “Psychotropic Substances/Toolkit/Form B/P and Supplement”

Please consider submitting this form using XML format.

This form should be completed and sent to:

International Narcotics Control Board

Vienna International Centre

P.O. Box 500, 1400 Vienna, Austria

Telephone: + (43) (1) 26060-4277 Facsimile: + (43) (1) 26060-5867 or 26060-5868

Email: [email protected], [email protected] Home page: www.incb.org

Form B/P

Page 2

Total quantities required annually for medical and scientific purposes

Form B/P may be used to submit assessments for all psychotropic substances to be used in the

country. Assessments should reflect the total domestic medical and scientific requirements for

one year. They should therefore include quantities to be manufactured domestically and not be

restricted to imports. Quantities needed for industrial purposes (i.e. to manufacture other substances)

should be included and the purposes should be indicated (i.e. qualitative and quantitative information

on final products). The assessments should further include requirements to be held in stock to meet

exceptional circumstances. Quantities required for exports or re-exports should not be included in the

assessments. Assessments of delta-9-THC should include quantities of natural and synthetic origin.

All Governments are encouraged to provide information on the method used to determine the

assessments furnished in Form B/P. In this context, the Guide on Estimating Requirements for

Substances under International Control, available at www.incb.org, might be useful. The Guide is

intended to assist competent national authorities in identifying methods for calculating the quantities

of controlled substances required for medical and scientific purposes and may assist authorities in

preparing the assessments of annual requirements for psychotropic substances.

Unlike estimates for narcotic drugs, the assessments for psychotropic substances are not required

to be confirmed by the International Narcotics Control Board (INCB).

INCB recommends that a revised Form B/P be submitted at least once every three years. INCB

will use reported assessments for reference during a three-year period unless a supplement to

previously submitted assessments is received. The quantities indicated on Form B/P will be used as a

guide by the authorities responsible for authorizing exports in exporting countries.

Assessments are updated on a weekly basis and placed on the INCB website at: www.incb.org,

under “Psychotropic Substances/Status of Assessments”.

Form B/P

Page 3

STATEMENT OF THE METHOD

Please provide here comments on the methods used in determining

the various assessments reported on this form and/or any changes.

One licenced company deals with the import mostly from USA of pure reference substances and solutions

(in methanol, ethanol and acetonitrile) (Reference Material (RM) and Certified Reference Material (CRM))

for the purpose of re-export to EU and Middle-East to research and forensic laboratories for scietific and

forensic purposes.

The use of Dexamfetamine, Lisdexamfetamine dimesylate and methylphenidate in the treatment of ADHD

has increased. Lisdexamfetamine dimesylate has been converted to Dexamfetamine.

delta-9-THC* - Bedrocan 5 cannabis products (flos and granular form) applied by doctors for specific

patients

Remarks

Form B/P

Page 4

Assessments of requirements for substances in Schedule II

Code Substance Kilograms Grams

PA 003 Amfetamine 120

PA 007 Amineptine 20

PA 008 AM-2201 20

PA 009 5F-APINACA (5F-AKB-48) 20

PA 010 5F-AMB-PINACA (5F-AMB, 5F-MMB-PINACA) 20

PA 011 ADB-BUTINACA 20

PB 008 2C-B 20

PC 011 AB-CHMINACA 20

PC 012 CUMYL-4CN-BINACA 20

PC 013 ADB-CHMINACA 20

PC 014 4-CMC (4-chloromethcathinone; clephedrone) 20

PC 015 CUMYL-PEGACLONE 20

PD 002 Dexamfetamine 2 920

PD 010 delta-9-THC* 2 500

PD 012 Diphenidine 20

PE 007 Ethylone 20

PE 008 Ethylphenidate 20

PE 010 Eutylone 20

PF 005 Fenetylline 20

PF 007 4-fluoroamphetamine (4-FA) 20

PF 008 FUB-AMB 20

PF 009 ADB-FUBINACA 20

PF 010 AB-FUBINACA 20

PG 002 GHB 3 000

PJ 001 JWH-018 20

PL 006 Levamfetamine 20

PL 007 Levomethamphetamine 20

PM 002 Mecloqualone 20

PM 005 Metamfetamine 20

PM 006 Methaqualone 20

PM 007 Methylphenidate 60 000

Form B/P

Page 5

PM 015 Metamfetamine racemate 20

PM 021 MDPV (3,4-methylenedioxypyrovalerone) 20

PM 022 Mephedrone (4-methylmethcathinone) 20

PM 023 Methylone (beta-keto-MDMA) 20

PM 024 Methoxetamine (MXE) 20

PM 025 MDMB-CHMICA 20

PM 026 Methiopropamine (MPA) 20

PM 027 4-methylethcathinone (4-MEC) 20

PM 028 5F-MDMB-PICA (5F-MDMB-2201) 20

PM 029 4-F-MDMB-BINACA 20

PM 030 MDMB-4en-PINACA 20

PM 031 3-Methoxyphencyclidine 20

PM 032 3-Methylmethcathinone 20

PN 009 N-benzylpiperazine (BZP) 20

PN 010 N-ethylnorpentylone (ephylone) 20

PN 011 N-ethylhexedrone 20

PP 005 Phencyclidine 20

PP 006 Phenmetrazine 20

PP 011 5F-ADB/5F-MDMB-PINACA 20

PP 018 AB-PINACA 20

PP 022 α-PVP 20

PP 023 4,4’-DMAR 20

PP 025 Pentedrone 20

PP 026 5F-PB-22 20

PP 027 alpha-PHP 20

PP 028 alpha-PiHP 20

PS 001 Secobarbital 20

PU 001 UR-144 20

PX 001 XLR-11 20

PZ 001 Zipeprol 20

Form B/P

Page 6

Assessments of requirements for substances in Schedule III

Code Substance Kilograms Grams

PA 002 Amobarbital 20

PB 004 Butalbital 20

PB 006 Buprenorphine 520

PC 001 Cyclobarbital 20

PC 009 Cathine 20

PF 002 Flunitrazepam 20

PG 001 Glutethimide 20

PP 002 Pentobarbital 176 000

PP 014 Pentazocine 20

Form B/P

Page 7

Assessments of requirements for substances in Schedule IV

Code Substance Kilograms Grams

PA 001 Amfepramone 20

PA 004 Alprazolam 5 000

PA 005 Allobarbital 20

PA 006 Aminorex 20

PB 001 Barbital 20

PB 002 Benzfetamine 20

PB 003 Bromazepam 8 500

PB 005 Butobarbital 20

PB 007 Brotizolam 20

PC 002 Camazepam 20

PC 003 Chlordiazepoxide 70

PC 004 Clobazam 1 200

PC 005 Clonazepam 3 600

PC 006 Clorazepate 20

PC 007 Clotiazepam 20

PC 008 Cloxazolam 20

PC 016 Clonazolam 20

PD 005 Delorazepam 20

PD 006 Diazepam 153 000

PD 013 Diclazepam 20

PE 001 Ethchlorvynol 20

PE 002 Ethinamate 20

PE 003 Estazolam 20

PE 004 Ethyl loflazepate 20

PE 005 Etilamfetamine 20

PE 009 Etizolam 20

PF 001 Fludiazepam 20

PF 003 Flurazepam 20

PF 004 Fencamfamin 20

PF 006 Fenproporex 20

PF 011 Flualprazolam 20

Form B/P

Page 8

PF 012 Flubromazolam 20

PH 001 Halazepam 20

PH 002 Haloxazolam 20

PK 001 Ketazolam 20

PL 001 Lefetamine, SPA 20

PL 003 Loprazolam 20

PL 004 Lorazepam 1 900

PL 005 Lormetazepam 20

PM 001 Mazindol 20

PM 003 Meprobamate 20

PM 008 Methylphenobarbital 20

PM 009 Methyprylon 20

PM 010 Medazepam 15 000

PM 012 Mefenorex 20

PM 016 Midazolam 3 500

PM 018 Mesocarb 20

PN 001 Nimetazepam 20

PN 002 Nitrazepam 2 000

PN 003 Nordazepam 20

PO 001 Oxazepam 900

PO 002 Oxazolam 20

PP 004 Phendimetrazine 20

PP 008 Phenobarbital 47 000

PP 009 Phentermine 20

PP 010 Pipradrol 20

PP 015 Pinazepam 20

PP 016 Prazepam 20

PP 019 Pyrovalerone 20

PP 020 Pemoline 20

PP 024 Phenazepam 50

PS 003 Secbutabarbital 20

PT 003 Temazepam 20

PT 004 Tetrazepam 20

Form B/P

Page 9

PT 005 Triazolam 25

PV 001 Vinylbital 20

PZ 002 Zolpidem 25 900